|Bid||3.7200 x 3000|
|Ask||3.7900 x 4000|
|Day's range||3.7537 - 3.9700|
|52-week range||2.4900 - 5.5300|
|Beta (5Y monthly)||1.93|
|PE ratio (TTM)||N/A|
|Earnings date||09 Aug 2022 - 15 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||6.00|
Allogene Therapeutics (ALLO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
If you want to know who really controls MannKind Corporation ( NASDAQ:MNKD ), then you'll have to look at the makeup of...
WESTLAKE VILLAGE, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, will showcase its mealtime insulin solutions and expanding efforts within the diabetes community at the American Diabetes Association’s 82nd Scientific Sessions, June 3-7 in New Orleans. “MannKind is committed to providing products that address unmet need